Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-014934
Filing Date
2024-02-14
Accepted
2024-02-14 07:20:39
Documents
88
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K sage-20231231.htm   iXBRL 10-K 3438638
2 EX-21.1 sage-ex21_1.htm EX-21.1 12099
3 EX-23.1 sage-ex23_1.htm EX-23.1 2827
4 EX-31.1 sage-ex31_1.htm EX-31.1 13861
5 EX-31.2 sage-ex31_2.htm EX-31.2 13840
6 EX-32.1 sage-ex32_1.htm EX-32.1 8821
7 EX-97 sage-ex97.htm EX-97 29929
8 GRAPHIC img93227711_0.jpg GRAPHIC 277520
9 GRAPHIC img93227711_1.jpg GRAPHIC 107908
  Complete submission text file 0000950170-24-014934.txt   14230901

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sage-20231231.xsd EX-101.SCH 1655045
90 EXTRACTED XBRL INSTANCE DOCUMENT sage-20231231_htm.xml XML 2614211
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36544 | Film No.: 24632265
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)